Comparison of the Therapeutic Effects of VR and VR + GnRHa in the Treatment of Cesarean Scar Diverticula
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Cesarean scar diverticula (CSD) is a novel recognized cause of postmenstrual abnormal uterine
bleeding in women. No clinical guidelines have been issued for the management of CSD. The
investigators have previously demonstrated that vaginal repair of CSD was an relative
effective treatment of CSD. However, only 28.2% of the CSD patients normalized to less than 7
days of menstruation, whereas 51.2% of women had 7 to 10 days of menstruation at 6 months
post vaginal repair. Postoperative menstruation may contribute to surgical site infections,
which may subsequently affect the healing of uterine scars. Treatment CSD patients with
gonadotropin-releasing hormone agonist (GnRHa) may has the potential to improve therapeutic
effects of vaginal repair. Therefore, the current multiple-center randomized controlled trial
was designed to evaluate whether the application of GnRHa in combination with vaginal repair
could achieve better clinical effects than those achieved by vaginal CSD repair alone.